Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3971-3980 Newer>

The Motley Fool August 3, 2007 Brian Lawler	Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies.
The Motley Fool August 3, 2007 Brian Orelli	Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note.
The Motley Fool August 3, 2007 Brian Orelli	Extrinsic Growth From Inverness The acquisitions that the medical company has made over the last year and a half will increase its growth potential. The biggest question is whether it overpaid for that privilege. Investors will need a few more quarters to figure out the full potential of the new, larger company.
The Motley Fool August 3, 2007 Billy Fisher	Stormy Waters at Wyeth The downward trend in the price of Wyeth shares may have painted a grim picture for the stock's future; however, the company has already demonstrated its ability to grow revenues despite the competition from generics.
BusinessWeek August 13, 2007 Arlene Weintraub	Putting Drug Ads Back In The Bottle Efforts to curb direct-to-consumer drug advertising are growing, but so far have met little success.
BusinessWeek August 13, 2007 Gene G. Marcial	From SemBiosys, A New Kind Of Insulin SemBiosys recombinant insulin could be launched by 2010, if approved.
Chemistry World August 2, 2007 Victoria Gill	Europe Poised for a Surge in Generic Drugs The European Medicines Agency's Committee for Medicinal Products for Human use has recommended the approval of a schizophrenia treatment which is the first generic drug to be assessed under Europe's centralized procedure.
The Motley Fool August 2, 2007 Brian Lawler	Human Genome Advances Human Genome Sciences updates investors on what to expect. The past quarter has been full of developments on their two lead drugs. Phase 3 studies for both are currently under way.
The Motley Fool August 2, 2007 Brian Lawler	United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note.
The Motley Fool August 2, 2007 Brian Orelli	98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news.
<Older 3971-3980 Newer> Return to current articles.